Advanced search×

Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum.

Audio, Transactions of the IRE Professiona... 92(4):483-7 (2008) PMID 18369065

To investigate the efficacy of intravitreal bevacizumab injections for treating choroidal neovascularisation (CNV) secondary to pseudoxanthoma elasticum (PXE).

DOI: 10.1136/bjo.2007.129916
Version: za2963e q8zaf q8zb5 q8zc8 q8zdb q8ze0 q8zf4 q8zg5

Similar articles you may find interesting…

  1. Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage

    Acta Ophthalmol 91(3):274-278 (2013) PMID 21952010

      There was more improvement in patients initially treated with rtPA and gas (14 letters; bevacizumab and gas eight letters) and not suffering from adverse events. The incidence of vitreous haemorrhages was significantly higher in the rtPA group (nine of 32 versus one of 13, p < 0.01). In both...
  2. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent ...

    Pediatr Blood Cancer (2013) PMID 23630159

    Reducing temozolomide from 150 to 100 mg/m(2) /day improved tolerability, and treatment with this lower temozolomide dose was feasible and convenient as outpatient therapy. Although responses were seen in Ewing sarcoma, the benefit of adding bevacizumab remains unclear. Pediatr Blood Cancer 2013;9...
  3. FACTORS PREDICTIVE OF OUTCOMES 1 YEAR AFTER 3 MONTHLY RANIBIZUMAB INJECTIONS AND AS-NEEDED REINJECTIONS FOR POLYPOIDAL CHOROIDAL VASCULOPATH...

    Retina (2013) PMID 23612049

    : After the initial 3 monthly injections, a mean ± standard deviation of 1.2 ± 1.1 as-needed injections was administered. The mean visual acuity improved significantly (P < 0.01) from 20/80 to 20/50. Better visual acuity and no history of photodynamic therapy or clusters of grape-like polypoidal le...